Mindray to Attend the 11th Credit Suisse Asian Investment Conference

Friday, March 21, 2008 General News J E 4
SHENZHEN, China, March 20 Mindray MedicalInternational Limited (NYSE: MR), a leading developer, manufacturer andmarketer of medical devices in China with a rapidly growing internationalpresence, today announced that Mr. Li Xiting, Mindray's president and co-chiefexecutive officer, will attend the 11th Credit Suisse Asian InvestmentConference held at the Shangri-la Hotel in Hong Kong, China from Monday, March31, 2008 to Thursday, April 3, 2008. Mr. Li will present on Wednesday, March 2,2008 from 4:20 to 5:00 p.m. Beijing/Hong Kong Time.

Mr. Li will discuss Mindray's recent developments and 2008 domestic andinternational strategy. The presentation will be webcast and will be availablelive and for replay on the Agenda section of Credit Suisse's Asian InvestmentConference website at: .

About Mindray

Mindray Medical International Limited is a leading developer, manufacturerand marketer of medical devices in China with a significant and growingpresence worldwide. Established in 1991, Mindray offers a broad range ofproducts across three primary business segments: patient monitoring & lifesupport products, in-vitro diagnostic products, and medical imaging systems.Mindray is headquartered in Shenzhen, China, and has 29 local sales andservice offices in China, as well as sales and service offices in Amsterdam,Istanbul, London, Mexico City, Moscow, Mumbai, Sao Paulo, Seattle, Toronto andVancouver. For more information, please visit .For investor inquiries please contact: In China: Susan Du Mindray Medical International Limited Tel: +86-755-2658-2518 Email: Justin Knapp Ogilvy Public Relations Worldwide, Beijing Tel: +86-10-8520-6556 Email: In the United States: Jeremy Bridgman Ogilvy Public Relations Worldwide, New York Tel: +1-212-880-5363

SOURCE Mindray Medical International Limited


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Nereus Pharmaceuticals Initiates Clinical Trial of...
Harris Corporation Awarded Contract to Develop Nat...